Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $165.11 is 20.96% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 167.99||$ 194.92|
|Low:||$ 164.67||$ 136.50|
ETFs with VRTX as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|5.47%||Invesco Dynamic Biotech & Genome ETF (PBE)||-4.37 (-7.96%)|
|5.14%||VanEck Vectors Biotech ETF (BBH)||+0.03 (0.03%)|
|4.26%||iShares Nasdaq Biotechnology Index Fund (IBB)||-5.42 (-4.95%)|
|4.05%||Invesco Russell Top 200 Pure Growth ETF (PXLG)||-1.28 (-2.53%)|
|*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past 100 days.|
Company Description (as filed with the SEC)
We invest in scientific innovation to create transformative medicines for serious diseases. Our business is focused on developing and commercializing therapies for the treatment of cystic fibrosis, or CF, and advancing our research and development programs in other diseases. Our marketed products are ORKAMBI (lumacaftor in combination with ivacaftor), KALYDECO (ivacaftor) and SYMDEKO (tezacaftor in combination with ivacaftor). Cystic Fibrosis Our goal is to develop treatment regimens that will provide benefits to all patients with CF and will enhance the benefits that currently are being provided to patients taking our medicines. Current Medicines ORKAMBI, KALYDECO and SYMDEKO are collectively approved to treat approximately 45% of the 75,000 CF patients in North America, Europe and Australia. ... More ...
Nasdaq Official Price
Nov. 16, 2018
Nov. 16, 2018